



VASCern

The European Network on Rare Multisystemic Vascular Diseases

**E-RARE 3
JOINT TRANSNATIONAL CALL 2017 (JTC 2017)
FOR TRANSNATIONAL RESEARCH PROJECTS FOR
INNOVATIVE THERAPEUTIC APPROACHES FOR RARE
DISEASES**

December, 7th 2016



E-RARE 3 CALL 2017 TIMELINE

*External reviewer
evaluation, Rebuttal stage,
Evaluation & Funding
decision*

*Eligibility Check
Peer review
evaluation*

**December 5th-
February 1, 2017,
5pm CEST.**

- Deadline for pre-proposal submission
- [Read](#) carefully the Call & Guidelines
- Contact [NCP](#)
- Register to the [electronic proposal system](#) (open in January)
- Use the [pre-proposal template](#)

End of April, 2017

- Communication of selection of pre-proposals, to be able to submit the full proposal

**June 2nd, 2017,
5pm CEST.**

- Deadline for full-proposal submission

**Selection of
projects by the
end of October
2017**



E-RARE 3 CALL 2017

Context:

- **Research needed** to provide knowledge for prevention, diagnosis, better care for Rare Diseases patients

- **Lack of resources** at several levels:
 - few scientists, scarcity of knowledge, fragmentation of research
 - limited number of patients per diseases
 - difficulties to gather necessary cohorts
 - databases (accessibility, size, standardization)
 - complexity of clinical phenotypes
 - need for interdisciplinary cooperation and approach to treatment

- **Very High EU added value** of cooperation

Aim:

- Enable scientists in different countries to build an effective collaboration on a common interdisciplinary research project based on complementarities and sharing of expertise, with a clear translational research approach



E-RARE 3 CALL 2017 SCOPE

- **Pre-clinical development of therapeutic approaches in suitable existing animal or cell models**
 - a. Cell-based therapy
 - b. Gene therapy
 - c. Pharmacological therapy
- A group of RD or a single RD following the European definition
- based on novel ideas stemming from consolidated previous results
- strong translational research orientation
- complementarity and synergetic interaction among partners
- Clear added value of transnational collaboration (critical mass, sharing resources)
- **Using existing European health research infrastructures** strongly encouraged: identify and design a long-term strategy in your proposal (ex: BBMRI, EATRIS, INFRAFRONTIER)

Excluded:

- a. Therapeutic approaches concerning rare infectious diseases, rare cancers and rare adverse drug events in treatments of common diseases
- b. Interventional clinical trials or any project enrolling patients
- c. Development of new cell or animal models. The relevant cell or animal model must be already established for the purpose of the project
- d. Surgery or radiation therapies



E-RARE 3 CALL 2017 ELIGIBILITY CRITERIA

Applicants (Academia, Clinical/Public Health Sector (research teams), Enterprise) must contact the [National Contact Point](#) for eligibility check + adherence to National regulations in the [Guideline for applicants](#) is mandatory

- Individual groups will be funded by individual national funding organisation participating to the call (**Austria, Belgium, Canada, Finland, France, Germany, Greece, Hungary, Israël, Italy, Japan, Latvia, Poland, Romania, Spain, Switzerland, Turkey**)
- Transnational projects with a **minimum of 3 eligible and a maximum of 6 eligible partners from at least 3 different countries**
- No more than 2 partners from the same country per consortium
- Encourage to **include partners from the underrepresented participating countries** (Hungary, Latvia, Poland, Romania, Turkey) – Maximum of participants increases then to 7/8. This will also count on the ranking of project proposals for funding
- 2 additional partners can join if securing their own funding
- Applicants shall avoid applying to different calls for the same research activities (double funding not allowed)



E-RARE 3 CALL 2017

EVALUATION CRITERIA

1/ Excellence	2/ Impact	3/ Quality & Efficiency of the implementation
<ul style="list-style-type: none">a) Clarity, pertinence of objectivesb) Credibility of the approach and methodologyc) Concept soundnessd) Innovativee) Feasibility (resources, time schedule)f) Competence, experience of the research partners	<ul style="list-style-type: none">a) Potential results and applicationsb) Added value of transnational collaboration (critical mass, harmonization of data, sharing resources,...)c) Effectivenessd) Involvement of patient organisations & representatives, industry	<ul style="list-style-type: none">a) Coherence & effectiveness of the work planb) Complementarityc) Appropriateness of the management structures and proceduresd) Budget and cost-effectiveness



E-RARE 3 CALL 2017 FUNDING MODEL

- National/regional fundings in a « virtual common pot »
- Applicants must contact their [NCP](#) for eligibility
- Involvement of Patient Organisations with research funding mandates possible. PO will develop a co-funding agreement with funding organisations
- Funding contracts: for Project coordinator and each research partners
- Funding granted for a maximum of 3 years, see specific national rules in the [call guidelines](#)
- Consortium agreement to be signed by partners
- Reporting: Brief annual scientific project reports and final report



USEFUL LINKS AND CONTACT

- Read the Call document: [here](#)
- Read the Call Guidelines: [here](#)
- Call forms: [here](#)
- Italy mandatory eligibility form: [here](#)
- French eligibility rules: [here](#)
- National Contact Points for national eligibility criteria and requirements: [here](#)
- Platform for submission: [here](#) (open in January)
- All information on the Call [here](#)
- [ERANET-E-RARE website](#)

Joint Call Secretariat:

Ms Maria Druet, mdruet@isciii.es

Office of EU and International Research project

National Institute of Health Carlos III

(+34) 91 822 2530



VASCern

The European Network on Rare Multisystemic Vascular Diseases

About our Network VASCern.eu

VASCern is a European Network gathering 31 highly specialised Healthcare Providers from 11 EU Member States and Patient Organisations in Rare Multisystemic Vascular Diseases.

It aims to facilitate and improve diagnosis, treatment and care for ALL patients suffering from Rare Multisystemic Vascular Diseases, thus enhancing access to care, and improving quantity and quality of life of these patients.

Contact us

Prof. Guillaume Jondeau
VASCern Network Coordinator
Cardiologist
Coordinator of [CRMR Marfan](http://CRMR-Marfan.org) Syndrome
and related Disorders, Paris, France
Coordinator of [FAVA-Multi](http://FAVA-Multi.fr), the French Network
on Rare Multisystemic Vascular Diseases
guillaume.jondeau@aphp.fr
0033 1 40 25 74 60

Marine Hurard
VASCern Project Manager
marine.hurard@aphp.fr
0033 1 40 25 80 66

<http://vascern.eu/contact/>

A Project supported by FAVA-Multi.fr